Abivax (NASDAQ:ABVX) Shares Gap Up – What’s Next?

Abivax SA Sponsored ADR (NASDAQ:ABVX) gapped up prior to trading on Wednesday . The stock had previously closed at $119.10, but opened at $124.86. Abivax shares last traded at $127.9990, with a volume of 416,625 shares changing hands.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Truist Financial set a $140.00 price target on shares of Abivax in a research report on Monday, November 24th. Guggenheim reiterated a “buy” rating and issued a $175.00 target price on shares of Abivax in a research note on Thursday, December 18th. Barclays initiated coverage on Abivax in a research report on Monday, October 13th. They set an “overweight” rating and a $142.00 price target on the stock. Wall Street Zen cut Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, Citizens Jmp boosted their target price on Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.42.

Abivax Stock Down 8.7%

The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The stock has a market cap of $9.00 billion, a P/E ratio of -27.63 and a beta of 0.68. The firm has a 50-day simple moving average of $119.93 and a two-hundred day simple moving average of $83.80.

Abivax (NASDAQ:ABVX) last announced its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The firm had revenue of ($4.92) million for the quarter. Equities research analysts expect that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ABVX. QP Wealth Management LLC bought a new stake in shares of Abivax in the fourth quarter valued at approximately $745,000. Avior Wealth Management LLC acquired a new position in Abivax in the 4th quarter valued at $377,000. Union Bancaire Privee UBP SA bought a new stake in shares of Abivax during the 4th quarter valued at $67,000. Tudor Investment Corp ET AL acquired a new stake in shares of Abivax during the 3rd quarter worth $2,792,000. Finally, FNY Investment Advisers LLC bought a new position in shares of Abivax in the third quarter worth $275,000. 47.91% of the stock is owned by institutional investors.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.